Clinical trials: Glaucoma,Open-Angle
Open-Angle Glaucoma, Ocular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT04285580
- Testing
- Bimatoprost SR, LUMIGAN
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- AbbVie
Glaucoma, Glaucoma, Open Angle
SOLX Titanium Sapphire Laser for Trabeculoplasty
Use of the Titanium Sapphire laser for laser trabeculoplasty to reduce intraocular pressure in patients with poorly controlled intraocular pressure on maximally tolerated medical therapy or prior failed laser trabeculoplasty.
- Trial name
- NCT00145535
- Testing
- SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT)
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 120 people
- Sponsor
- SOLX, Inc.
Glaucoma
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
- Trial name
- NCT00966940
- Testing
- Travoprost 0.004% ophthalmic solution (TRAVATAN), Tafluprost 0.0015% ophthalmic solution
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Glaucoma Open-Angle Primary, Ocular Hypertension
Open-Label Study of Safety of H1337 in Healthy Volunteers
The trial will evaluate the safety of one dose regimen of H-1337 [1% twice daily (b.i.d.)] in both eyes in healthy volunteers.
- Trial name
- NCT06572397
- Testing
- H-1337 1.0%
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- D. Western Therapeutics Institute, Inc.
Open-angle Glaucoma, Ocular Hypertension
Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
This study was to compare the safety and efficacy of the preservative-free formulation of 0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension.
- Trial name
- NCT01026831
- Testing
- Preservative-Free Tafluprost, Comparator: timolol
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUS (NCT02061683)
- Testing
- Bimatoprost 0.03%
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Allergan
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH
Ocular Hypertension, Open-Angle Glaucoma
A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG
The objective of this study is to investigate how the intraocular pressure (IOP)-lowering effect of the L-PPDS is altered by adjunctive Xalatan therapy.
- Trial name
- NCT01037036
- Testing
- Latanoprost Punctal Plug Delivery System, Xalatan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mati Therapeutics Inc.
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used…
- Trial name
- NCT01342081
- Testing
- DE-111 ophthalmic solution, Tafluprost ophthalmic solution 0.0015%, Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 489 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Open-Angle
Travoprost Intraocular Implant + iStent Infinite
Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and…
- Trial name
- NCT06066645
- Testing
- Travoprost Intraocular Implant, iStent infinite
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma
A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma
The goal of this study is to learn about outcomes after bio-reinforced canaloplasty surgery in patients with OAG. The key question the study aims to answer is: How much does the surgical procedure lower pressure inside the eye…
- Trial name
- BOOST (NCT07520175)
- Testing
- AlloSpan Canal Platform Bio-Reinforced Canaloplasty
- Where
- 9 sites in United States
- Volunteers
- 300 people
- Sponsor
- Iantrek, Inc.
Open-angle Glaucoma, Ocular Hypertension
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the IOP-lowering efficacy of a combination of Travoprost / Timolol maleate, dosed in the morning or in the evening, in patients with open-angle glaucoma or ocular hypertension, who have an…
- Trial name
- NCT00759239
- Testing
- Travoprost 0.004% / Timolol maleate 0.5%
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Alcon Research
Glaucoma
Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients
The purpose of the this study is to collect safety and efficacy data on Focused Ultrasound treatment (UCP procedure) in open angle glaucoma patients without previous glaucoma surgery.
- Trial name
- NCT02789293
- Testing
- EyeOP1 device
- Where
- 4 sites in Belgium, Israel and 2 more
- Volunteers
- 80 people
- Sponsor
- EyeTechCare
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98
The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after twelve months of treatment in Japanese subjects.
- Trial name
- NCT00047593
- Testing
- IOP Lowering Medications
- Where
- 3 sites in United States
- Sponsor
- Alcon Research
Glaucoma, Open-Angle
Early Evaluation of the Beacon Aqueous Microshunt in Patients Refractory to Drug Therapy in the European Union
This is prospective, non-randomized, single-arm study to assess the safety and effectiveness of lowering intraocular pressure with the Beacon Aqueous Microshunt. A total of 65 subjects will be enrolled at five centers.
- Trial name
- EARLY BIRD EU (NCT03634319)
- Testing
- Beacon Aqueous Microshunt
- Where
- 2 sites in Germany
- Volunteers
- 10 people
- Sponsor
- MicroOptx
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
- Trial name
- NCT03131167
- Testing
- SHP639 (n=60)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Shire
Open-angle Glaucoma
Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma
A single centre, open label, study to assess the safety, tolerability and biodegradation of PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).
- Trial name
- NCT03604328
- Testing
- PA5108
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- PolyActiva Pty Ltd
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Normal Tension Glaucoma, Primary Open-angle Glaucoma
Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl
This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease.
- Conditions
- Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect, Ocular Hypertension
- Trial name
- NOPAPS (NCT05279716)
- Testing
- Eybelis ophthalmic solution 0.002%
- Where
- 8 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Santen Pharmaceutical Asia Pte. Ltd.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or…
- Trial name
- NCT01291108
- Testing
- AGN-210669, bimatoprost, bimatoprost vehicle
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Allergan